Overcoming obstacles in pharmacogenomic strategies for antiplatelet drugs: are we RAPID enough?

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.13, Iss.10, 2012-07, pp. : 1105-1108

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Antiplatelet Drugs - Do We Need New Options?: With a Reappraisal of Direct Thromboxane Inhibitors

By Coccheri Sergio

Drugs, Vol. 70, Iss. 7, 2010-05 ,pp. : 887-908

Adis International

Access to resources Recommend Favorite

New antiplatelet drugs

By Reilly T. Mousa S. Racanelli A.

Expert Opinion on Emerging Drugs, Vol. 4, Iss. 1, 1999-01 ,pp. : 197-208

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenomic characterization of US FDA-approved cytotoxic drugs

By Peters Eric J Motsinger-Reif Alison Havener Tammy M Everitt Lorraine Hardison Nicholas E Watson Venita G Wagner Michael Richards Kristy L Province Mike A McLeod Howard L

Pharmacogenomics, Vol. 12, Iss. 10, 2011-10 ,pp. : 1407-1415

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic strategies against resistance development in microbial infections

By Ziebuhr Wilma Xiao Ke Coulibaly Boubacar Schwarz Roland Dandekar Thomas

Pharmacogenomics, Vol. 5, Iss. 4, 2004-06 ,pp. : 361-379

Future Medicine

Access to resources Recommend Favorite

Pharmacological Strategies for Overcoming Multidrug Resistance

Current Drug Targets, Vol. 7, Iss. 7, 2006-07 ,pp. : 861-879

Bentham Science Publishers

Access to resources Recommend Favorite